Zum Hauptinhalt springen Zur Suche springen Zur Hauptnavigation springen
Beschreibung
Virtually no research is targeted at developing medicines for tropical diseases as the expected market returns from R&D into these diseases in the private pharmaceuticals sector are too low. Frank Müller-Langer addresses the market failure with respect to R&D for medicines for tropical diseases and the lack of short-term access to affordable medicines in poor countries. The author analyzes additional push and pull mechanisms to stimulate R&D for pharmaceutical products alongside patent protection which may help mitigate the problem of those consumers in poor countries who lack access to affordable medicines. Furthermore, he reasons that a global regime of banning parallel trade from low-income countries to high-income countries is desirable from a developing country's perspective.
Virtually no research is targeted at developing medicines for tropical diseases as the expected market returns from R&D into these diseases in the private pharmaceuticals sector are too low. Frank Müller-Langer addresses the market failure with respect to R&D for medicines for tropical diseases and the lack of short-term access to affordable medicines in poor countries. The author analyzes additional push and pull mechanisms to stimulate R&D for pharmaceutical products alongside patent protection which may help mitigate the problem of those consumers in poor countries who lack access to affordable medicines. Furthermore, he reasons that a global regime of banning parallel trade from low-income countries to high-income countries is desirable from a developing country's perspective.
Über den Autor
Dr. Frank Müller-Langer is a research fellow at the Max Planck Institute for Intellectual Property, Competition and Tax Law and academic coordinator of the International Max Research School for Competition and Innovation in Munich. He obtained his doctorate in economics from Hamburg University in 2008.
Zusammenfassung
Virtually no research is targeted at developing medicines for tropical diseases as the expected market returns from R&D into these diseases in the private pharmaceuticals sector are too low. Frank Müller-Langer addresses the market failure with respect to R&D for medicines for tropical diseases and the lack of short-term access to affordable medicines in poor countries. The author analyzes additional push and pull mechanisms to stimulate R&D for pharmaceutical products alongside patent protection which may help mitigate the problem of those consumers in poor countries who lack access to affordable medicines. Furthermore, he reasons that a global regime of banning parallel trade from low-income countries to high-income countries is desirable from a developing country's perspective.
Inhaltsverzeichnis
The TRIPS Agreement and Access to Patented Medicines.- Economic Analysis of Patents.- Patent Protection in the Developing World: Theory and Evidence.- Legal and Economic Analysis of Parallel Imports.- Solutions for the Problem of Underinvestment in R&D for Medicines for Neglected Infectious and Tropical Diseases.- Conclusion and Ideas for Further Research.
Details
Erscheinungsjahr: 2009
Fachbereich: Betriebswirtschaft
Genre: Recht, Sozialwissenschaften, Wirtschaft
Rubrik: Recht & Wirtschaft
Medium: Taschenbuch
Reihe: Ökonomische Analyse des Rechts
Inhalt: xix
297 S.
8 s/w Illustr.
297 p. 8 illus.
ISBN-13: 9783834917300
ISBN-10: 3834917303
Sprache: Englisch
Einband: Kartoniert / Broschiert
Autor: Müller-Langer, Frank
Redaktion: Behrens, Peter
Eger, Thomas
Holler, Manfred
Ott, Claus
Schäfer, Hans-Bernd
Hersteller: Gabler Verlag
Betriebswirtschaftlicher Verlag Dr. Th. Gabler
Ökonomische Analyse des Rechts
Verantwortliche Person für die EU: Springer Gabler in Springer Science + Business Media, Tiergartenstr. 15-17, D-69121 Heidelberg, juergen.hartmann@springer.com
Maße: 210 x 148 x 20 mm
Von/Mit: Frank Müller-Langer
Erscheinungsdatum: 28.07.2009
Gewicht: 0,466 kg
Artikel-ID: 101634578

Ähnliche Produkte